Clinical trials: Restenosis
Ischemic Heart Disease, Angina Pectoris
Physiology and Residual Ischemia After Percutaneous Coronary Intervention
Despite optimal angiographic result after stent implantation, a number of patients will undergo repeat angiography within 1 year of index procedure.
- Conditions
- Ischemic Heart Disease, Angina Pectoris, Chest Pain, Coronary Artery Disease
- Trial name
- EASY-PRIPCI (NCT04494750)
- Where
- Canada
- Volunteers
- 260 people
- Sponsor
- Laval University
Coronary Artery Disease
Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents
For lesions which develop restenosis after a drug-eluting stent, it is not known which the right strategy to use is, implantation of the same type of DES as the initial one or a DES with a different drug.
- Trial name
- DESIRE-2 (NCT00598715)
- Testing
- Sirolimus eluting stent, Paclitaxel-eluting stent
- Where
- 2 sites in Germany
- Volunteers
- 450 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Intracranial Atherosclerotic Disease (ICAD), Intracranial Arterial Stenosis
Photon-counting CT for Intracranial Stent Assessment
Intracranial atherosclerotic disease is an important cause of ischemic stroke, and intracranial stent implantation is increasingly used for patients with severe stenotic lesions.
- Conditions
- Intracranial Atherosclerotic Disease (ICAD), Intracranial Arterial Stenosis, Stent Restenosis, Ischemic Stroke
- Trial name
- NCT07769814
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xin Lou
Coronary Artery Disease
Progenitor Cells Role in Restenosis and Atherosclerosis
The aim of this study is to prospectively investigate the relationship of circulating endothelial progenitor cells at time of percutaneous coronary intervention to the subsequent development of in-stent restenosis or progression…
- Trial name
- PROCREATION (NCT01575431)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Roma La Sapienza
Coronary Artery Disease
Evaluation of the GTX™ 5126 DES Coronary Stent System in the Treatment of Patients With a Lesion in the Coronary Artery
The GTX™ Drug Eluting Coronary Stent System is intended for the treatment of patients with a lesion in the coronary artery.
- Trial name
- NCT00777842
- Testing
- GTX™ Drug Eluting Coronary Stent System
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Cook Group Incorporated
In-stent Coronary Artery Restenosis
Prognostic Assessment of Different Pattern of Bifurcation Restenosis
The LATINA registry aims at assessing a new classification of bifurcation restenosis in the prediction of major adverse cardiac events in patients who have previously undergone a succesful percutaneous bifurcation intervention.
- Trial name
- LATINA (NCT01411475)
- Testing
- Bifurcation restenosis classification
- Where
- 2 sites in Italy
- Sponsor
- Ospedale Santa Maria Goretti
Femoropopliteal In-Stent Restenosis
First in Human Study of Winsor Laser Catheter: A Prospective Registry to Evaluate The Safety and Performance of the Winsor Laser Catheter in the Treatment of In-Stent Restenosis
The study will evaluate the procedural safety and efficacy of the Winsor Laser Catheters for the treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
- Trial name
- NCT01962389
- Testing
- Winsor Laser Catheter
- Where
- Colombia
- Sponsor
- Spectranetics Corporation
In-Stent Restenosis
P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses
The aim of the study is to assess the safety and efficacy of the Paclitaxel-eluting PTCA-balloon in the treatment of in-stent restenoses in native coronary arteries with reference diameters between 2.5 mm and 3.5 mm and ≤ 22 mm…
- Trial name
- NCT00393315
- Testing
- paclitaxel coated balloon catheter
- Where
- 10 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University Hospital, Saarland
Ischemic Heart Disease, Restenosis
Treatment of Bifurcation Lesions by SINGLE STENT and KISSing Balloon Trial
The use of DES have not diminished the need of improved treatment strategies , especially the treatment of bifurcation lesions still leave much to be clarified.
- Trial name
- SINGLEKISS (NCT00798954)
- Testing
- Sirolimus-eluting coronary stent (Cypher), Paclitaxel-eluting stent (TAXUS)
- Where
- 17 sites in Japan
- Volunteers
- 800 people
- Sponsor
- Vulnerable Plaque Society
Coronary Artery Stenosis
Biorest Liposomal Alendronate With Stenting sTudy (BLAST)
The main objective of this study is to assess the safety and efficacy of Liposomal Alendronate in the treatment of de novo stenotic lesions in native coronary arteries in a population undergoing PCI with implantation of a bare…
- Trial name
- BLAST (NCT00739466)
- Testing
- Liposomal Alendronate
- Where
- 12 sites in Israel
- Volunteers
- 226 people
- Sponsor
- BIOrest Ltd.
Coronary Disease
Sirolimus- and Paclitaxel-Eluting Stents for Small Vessels (ISAR-SMART-3)
The purpose of this study is to compare the efficacy of paclitaxel- and sirolimus-eluting stents to prevent re-blockage of small coronary arteries
- Trial name
- NCT00146575
- Testing
- Sirolimus-eluting stent (Cypher), Paclitaxel-eluting stent (Taxus)
- Where
- 2 sites in Germany
- Volunteers
- 360 people
- Sponsor
- Deutsches Herzzentrum Muenchen
In-stent Restenosis
Role of Novel Biomarkers Associated With In-stent Restenosis After Percutaneous Coronary Intervention
To study the relation between ISR and neutrophil-to-lymphocyte ratio (NLR), novel biomarkers (high-sensitivity CRP (hs-CRP), bone morphogenetic protein-2 (BMP-2) and other risk factors (age, sex, smoking, hypertension, diabetes…
- Trial name
- NCT06148441
- Testing
- bone morphogenetic protein-2 (BMP-2)
- Volunteers
- 100 people
- Sponsor
- Assiut University
Coronary Artery Disease, Stent Restenosis
Intracoronary Optical Coherence Tomography Guidance Vs. Angiography Only Guidance for Treatment of Coronary In-stent Restenosis
Although advances in drug-eluting stents (DES) have substantially reduced the risk of coronary in-stent restenosis (ISR) and the need for target lesion revascularisation (TLR), ISR persists.
- Conditions
- Coronary Artery Disease, Stent Restenosis, STENT
- Trial name
- INSIDE OCT (NCT06779110)
- Testing
- Percutaneous Coronary Intervention
- Where
- 12 sites in Italy
- Volunteers
- 360 people
- Sponsor
- San Luigi Gonzaga Hospital
Carotid Arteriosclerosis, Carotid Stenosis
Residual Stenosis and Restenosis Following Carotid Endarterectomy With Primary Closure, A Prospective Tracking Study
This prospective, multicenter observational study aims to evaluate the incidence, timing, and characteristics of residual and recurrent (restenosis) carotid artery stenosis following carotid endarterectomy (CEA) with primary…
- Conditions
- Carotid Arteriosclerosis, Carotid Stenosis, Brain Stroke
- Trial name
- RECEPT (NCT07057297)
- Where
- Czechia
- Volunteers
- 300 people
- Sponsor
- Charles University, Czech Republic
In-Stent Restenosis
A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR) - Long Lesion Cohort
The purpose of the AGENT IDE study is to assess the safety and effectiveness of the Agent Paclitaxel Coated PTCA Balloon Catheter in patients with in-stent restenosis (ISR) of a previously treated lesion of up to 36 mm in length…
- Trial name
- AGENT IDE (NCT06492174)
- Testing
- AGENT DCB 40 mm
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease, Coronary Restenosis
Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR
AbsorbISR is a randomized, controlled trial, single center, prospective, not blinded to evaluate two strategies of in stent restenosis treatment: Implantation of drug eluting bioresorbable stent scaffold Absorb® vs.
- Trial name
- AbsorbISR (NCT02474485)
- Testing
- BVS Absorb implantation., DEB Sequent Please inflation., Control coronary angiography.
- Where
- Switzerland
- Volunteers
- 53 people
- Sponsor
- SIS Medical AG
Coronary Angioplasty, Restenosis
Optimal Strategy to Correct Stent underexpAnsion in Resistant Lesions
Percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) accounts for 5-10% of PCI. ISR may be linked to mechanical complications mainly under-expansion (UE), neointimal hyperplasia and/or neoatherosclerosis.
- Conditions
- Coronary Angioplasty, Restenosis, Lithotripsy, Restenosis of Coronary Artery Stent
- Trial name
- OSCAR (NCT07316504)
- Testing
- Intravascular lithotripsy, Balloon
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Clermont-Ferrand
Restenosis
Treatment of Coronary In-Stent Restenosis
The purpose of this study is to compare efficacy of coronary in-stent restenosis therapy using drug eluting paclitaxel-coated balloon catheters with the latest generation of drug eluting stents releasing everolimus.
- Trial name
- TIS (NCT01735825)
- Testing
- paclitaxel-coated balloon catheter with Iopromide coating, drug eluting stent with everolimus, seal-wing paclitaxel-eluting balloon catheter
- Where
- Czechia
- Volunteers
- 199 people
- Sponsor
- University Hospital Ostrava
Coronary Artery Disease, Restenosis
Culotte Technique Versus TAP Stunting for the Treatment of de Novo Coronary Bifurcation Lesion With Drug-eluting Stents
BBK- 2 - study: STUDY-SUMMARY Background: The need for stenting of the main and side branch (double stenting) in the treatment of coronary bifurcation lesion primarily depends on the complexity of the bifurcation lesion.
- Trial name
- BBK2 (NCT01267838)
- Testing
- PCI
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- University Heart Center Freiburg - Bad Krozingen
Coronary Artery Disease
SONICURE（SONICracker for the Treatment of UndeRExpansion）
The first-phase study is a prospective, single-group observational study. It plans to recruit patients with in-stent restenosis caused by poor stent expansion in the coronary artery.
- Trial name
- NCT06924736
- Testing
- Intravascular Shockwave Therapy Device / Disposable Coronary Shockwave Catheter, Non - compliant balloon dilatation catheter
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Bluesail Boyuan Medical Technology Co., Ltd.